India has purchased 500 million doses of the Oxford University-AstraZeneca vaccine candidate, one billion from the United States company Novavax and 100 million doses of the Sputnik V candidate from Russia's Gamaleya Research Institute, according to the US-based Duke University Global Health Innovation Center.